MedTrace Logo

The Canadian Glomerulonephritis Registry and Translational Research Initiative

NCT03460054 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-03-09

No results posted yet for this study

Summary

Glomerulonephritis (GN) is one of the most important causes of kidney failure in Canada. These comprise a group of "rare" diseases (\<5 per 250,000 population), yet GN is a leading cause of kidney failure and accounts annually for close to 20% of incident cases of end stage kidney disease (ESKD) in Canada. Prevention of progression to kidney failure is possible, however several barriers and gaps in knowledge challenge our ability to provide patients with individualized effective therapy. These include a lack of sensitive non-invasive tools for monitoring disease activity, prognosis, and response to therapy. A gap in understanding of the core molecular processes underlying the development and progression of GN, and a lack of cohesive networks for evaluation of novel treatment approaches contribute to a lack of targeted and personalized therapies for GN. To address these challenges we will create a national, multi-dimensional platform for application of human-based molecular research and advanced therapeutics in GN.

Conditions

  • Glomerular Nephritis

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • Providence Health & Services

    collaborator OTHER

  • Foothills Medical Centre

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Queen Elizabeth II Health Sciences Centre

    collaborator OTHER

  • CHU de Quebec-Universite Laval

    collaborator OTHER

  • The Ottawa Hospital

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Heather Reich, MD · Nephrologist

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2022-12-30
Completion
2023-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460054 on ClinicalTrials.gov